Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Meetings
Meetings
Most popular
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Best of the 16th WCLC in Athens, Greece
lungcanc
Best of the 16th World Conference on Lung Cancer in Peru
Best of IASLC WCLC 2016
Highlights from the NCI Post-Treatment Surveillance Workshop
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Top Science in Lung Cancer Featured at WCLC 2018
lungcanc
Single-Agent Pembrolizumab Active Against STK11– and KEAP1– Mutated NSCLC According to...
lungcanc
Honoring Superb Advocacy at the 13th Annual Prevent Cancer Quantitative Imaging...
lungcanc
Societies Join Forces to Host Seventh European Lung Cancer Conference
lungcanc
Inaugural LATAM Awards
lungcanc
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
lungcanc
2017 Lung Cancer SPORE Workshop
lungcanc
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune...
lungcanc
Highlights from IASLC WCLC 2016
lungcanc
WCLC Plenary Symposia to Include Practice-Changing Research Presentations
lungcanc
1
2
3
...
6
Page 1 of 6
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
